Drug Search Results
More Filters [+]

Soblidotin

Alternative Names: soblidotin, TZT-1027
Latest Update: 2022-07-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MAPK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Soblidotin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Sarcoma|Liver Cancer|Soft Tissue Cancer|Lung Cancer|Bone Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-001108-11

P2

Terminated

Liver Cancer|Sarcoma|Lung Cancer|Soft Tissue Cancer|Bone Cancer

2021-01-13

CDR0000310138

P2

Completed

Sarcoma

2005-12-01

CDR0000301749

P2

Completed

Non-Small-Cell Lung Cancer

2005-05-01

DAIICHI-1027A-PRT008

P1

Withdrawn

Oncology Solid Tumor Unspecified

None

Recent News Events